Published in J Clin Oncol on October 01, 1999
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Requirements for clinical PET: comparisons within Europe. Eur J Nucl Med Mol Imaging (2004) 2.75
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res (2010) 1.40
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging (2008) 1.31
FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer (2002) 1.29
Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2007) 1.22
FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging (2005) 1.20
Risk stratification of solitary pulmonary nodules by means of PET using (18)F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging (2010) 1.17
Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging (2005) 1.17
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 1.11
Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging (2009) 1.08
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging (2008) 1.07
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging (2005) 1.06
Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax (2007) 1.05
Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification. Radiol Oncol (2013) 1.02
Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.01
Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2005) 1.00
Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. PLoS One (2014) 0.97
Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging (2004) 0.97
18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol (2007) 0.97
Predictive and prognostic value of FDG-PET. Cancer Imaging (2008) 0.96
Positron emission tomography/computerized tomography in lung cancer. Quant Imaging Med Surg (2014) 0.89
Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat (2015) 0.89
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg (2009) 0.88
Prognostic value of metabolic tumor burden in lung cancer. Chin J Cancer Res (2013) 0.88
Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer (2002) 0.87
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS One (2014) 0.86
Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol (2013) 0.86
The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg (2009) 0.86
Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiat Oncol (2014) 0.85
Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma. PLoS One (2013) 0.85
FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications. Korean J Radiol (2008) 0.85
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging (2010) 0.84
Validation of automatic target volume definition as demonstrated for 11C-choline PET/CT of human prostate cancer using multi-modality fusion techniques. Acad Radiol (2010) 0.82
Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer. Ann Thorac Surg (2016) 0.82
Advances in positron emission tomographic imaging of lung cancer. Proc Am Thorac Soc (2005) 0.82
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol (2010) 0.81
The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2013) 0.81
Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging (2015) 0.81
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer (2014) 0.80
PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep (2013) 0.80
The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol (2016) 0.79
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol (2014) 0.78
Demonstrating Intertumoural Differences in Vascular-Metabolic Phenotype with Dynamic Contrast-Enhanced CT-PET. Int J Mol Imaging (2011) 0.78
Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer. Tuberc Respir Dis (Seoul) (2015) 0.78
Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer. Radiat Oncol (2014) 0.78
Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg (2003) 0.77
Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer. Ann Nucl Med (2015) 0.77
Predicting tumour response. Cancer Imaging (2013) 0.77
Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification. Oncol Lett (2010) 0.77
Semi-quantitative investigation of primary tumor and bone metastasis in lung cancer patients using the PET-CT approach. Int J Clin Exp Med (2014) 0.77
[18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma. Int J Clin Oncol (2014) 0.76
Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer. Cancer Sci (2015) 0.75
Pretreatment tumor standardized uptake value as a prognostic factor in primary head and neck squamous cell carcinoma. Mol Clin Oncol (2014) 0.75
Predicted extracapsular invasion of hilar lymph node metastasis by fusion positron emission tomography/computed tomography in patients with lung cancer. Mol Clin Oncol (2015) 0.75
Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection. Medicine (Baltimore) (2017) 0.75
Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma. Braz J Med Biol Res (2015) 0.75
Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer. Medicine (Baltimore) (2016) 0.75
The imaging of small pulmonary nodules. Transl Lung Cancer Res (2017) 0.75
Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report. Chin J Cancer Res (2015) 0.75
Advances in recurrence and malignant transformation of sinonasal inverted papillomas. Oncol Lett (2017) 0.75
Amiodarone and the development of ARDS after lung surgery. Chest (1994) 2.96
Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax (2005) 1.71
Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer (1998) 1.57
The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J (2006) 1.56
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant (1999) 1.55
Lymphocytic bronchiolitis after lung transplantation is associated with daily changes in air pollution. Am J Transplant (2012) 1.47
Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation. Am J Transplant (2014) 1.43
Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid (2001) 1.38
Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group. Ann Oncol (1998) 1.38
Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma. Am J Respir Crit Care Med (1998) 1.36
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J (2001) 1.34
Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl (2001) 1.32
Clinical spectrum of endobronchial tuberculosis in elderly patients. Arch Intern Med (1990) 1.30
Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am J Respir Cell Mol Biol (1999) 1.28
The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol (2000) 1.26
Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol (1998) 1.25
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J (2007) 1.13
The effects of 5-HT on cholinergic contraction in human airways in vitro. Eur Respir J (1999) 1.13
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer (2003) 1.06
A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J (2008) 1.03
Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med (2006) 1.02
Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg (1997) 1.01
Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol (1998) 0.98
A fatal case of cholestatic liver failure probably related to gemcitabine. Ann Oncol (2000) 0.96
Extended preservation of ischemic pulmonary graft by postmortem alveolar expansion. Ann Thorac Surg (1997) 0.93
N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells. Eur Respir J (2003) 0.91
Giant cell interstitial pneumonia (hard metal lung disease, cobalt lung). Semin Respir Crit Care Med (2001) 0.91
Anechoic halo in solid liver tumors: sonographic, microangiographic, and histologic correlation. Radiology (1985) 0.90
Modulation by cAMP of IL-1beta-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur Respir J (2003) 0.90
Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg (1998) 0.90
Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer (1994) 0.88
Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med (1998) 0.88
Tracheal side effects of endoscopic balloon tracheal occlusion in the fetal lamb model. Eur J Obstet Gynecol Reprod Biol (2000) 0.87
The effect of cigarette smoking on exhaled nitric oxide in mild steroid-naive asthmatics. Chest (1999) 0.87
Mechanisms of interleukin 1beta-induced human airway smooth muscle hyporesponsiveness to histamine. Involvement of p38 MAPK NF-kappaB. Am J Respir Crit Care Med (2001) 0.87
FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med (1998) 0.86
Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp Lung Res (2010) 0.86
Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. Lung Cancer (2001) 0.84
Relation between different methods for analysing ST segment deviation and infarct size as assessed by positron emission tomography. Heart (2004) 0.84
Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol (1997) 0.84
Broncholithiasis: rare but still present. Respir Med (1998) 0.83
Renal transplantation in Indo-Asian patients in the UK. Am J Transplant (2006) 0.83
Warm ischemic tolerance in collapsed pulmonary grafts is limited to 1 hour. Ann Surg (1998) 0.83
Intimal hyperplasia after long-term venous catheterization. Eur Surg Res (2000) 0.81
Sleeve-related thrombosis: a new form of catheter-related thrombosis. Thromb Res (2001) 0.81
External cooling of warm ischemic rabbit lungs after death. Ann Thorac Surg (1996) 0.80
Effect of loop diuretics on cholinergic neurotransmission in human airways in vitro. Thorax (1994) 0.80
Pulmonary cell death in warm ischemic rabbit lung is related to the alveolar oxygen reserve. J Heart Lung Transplant (1998) 0.80
Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. Occup Environ Med (1997) 0.80
Clinical value of gallium-67 scintigraphy in evaluation of fever of unknown origin. Clin Infect Dis (1994) 0.80
Kinetics of an intratracheally administered chromium catalyst in rats. J Toxicol Environ Health A (2003) 0.80
Alveolar expansion itself but not continuous oxygen supply enhances postmortem preservation of pulmonary grafts. Eur J Cardiothorac Surg (1998) 0.80
Normal thoracoabdominal motions. Influence of sex, age, posture, and breath size. Am J Respir Crit Care Med (1995) 0.79
Assertiveness training in a preventive drug education program. J Drug Educ (1984) 0.78
Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer (2001) 0.78
Is there a role for measuring exhaled nitric oxide in lung transplant recipients with chronic rejection? J Heart Lung Transplant (1998) 0.77
Kinetics and cellular localisation of putrescine uptake in human lung tissue. Thorax (1993) 0.77
Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg (1995) 0.77
Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Mod Pathol (1995) 0.77
Possible recurrence of desquamative interstitial pneumonitis in a single lung transplant recipient. Eur Respir J (1998) 0.77
5-HT modulates noncholinergic contraction in guinea pig airways in vitro by prejunctional 5-HT1-like receptor. J Appl Physiol (1985) (1994) 0.76
Opioids modulate the cholinergic contraction but not the nonadrenergic relaxation in guinea-pig airways in vitro. Eur Respir J (1996) 0.76
New idiopathic pulmonary fibrosis guidelines: some unresolved questions. Am J Respir Crit Care Med (2012) 0.76
Microscopic haematuria in giant cell arteritis. Clin Rheumatol (2002) 0.76
Putrescine accumulation in human pulmonary tumours. Br J Cancer (1996) 0.75
Hormonal treatment in advanced non-small cell lung cancer: fact or fiction? Eur Respir J (1996) 0.75
Cimetidine plus propantheline for chronic pancreatitis. N Engl J Med (1978) 0.75
Renal thorium deposition associated with transitional cell carcinoma: radiologic demonstration in two patients. Radiology (1988) 0.75
SIADH and acute lung rejection. J Heart Lung Transplant (1997) 0.75
The effects of 8-hydroxy-2-(di-n-propylamino)tetralin on the cholinergic contraction in guinea pig and human airways in vitro. Am J Respir Crit Care Med (1998) 0.75